# OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

> **NCT07140783** · PHASE3 · RECRUITING · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Vision Loss Night
- Vision Disorders

## Interventions

- **DRUG:** 0.75% Phentolamine Ophthalmic Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07140783
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140783, "OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07140783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*